Skip to content
Company Analysis

AbbVie Inc. ABBV

A comprehensive view of key metrics, scores, and financial health for AbbVie Inc.

Overview of AbbVie Inc.

ABBV NYQ
Healthcare Drug Manufacturers - General Mega Cap
AbbVie Inc. (ABBV), is a Mega Cap company, in the Drug Manufacturers - General industry, last closed at $219.68, about 66.2% overvalued vs fair value, +2.4% 1Y return, placing in the top 10% of its sector.
$219.68
-2.52%
As of March 13, 2026
Previous close • Vol 90d: 26.6%
52-Week Range
Market Cap
$388.43B
Enterprise Value
$452.08B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for AbbVie Inc..

Top Beats

Quick Facts

Website https://www.abbvie.com
HQ North Chicago, IL
Employees 57,000
Fiscal year Dec 31

Next Events

Earnings May 1 Estimated
Dividend May 15 Ex-div: Apr 15

Fair Value Snapshot

Bear Base Bull
$68
$74
$81
Current: $219.68 -66% vs base

Engine Room Money Flow™

Mega Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
56.33B
8.6%%
Gross Profit
39.43B
29.8%%
R&D Expense
12.79B
-28.9%%
Operating Income (EBIT)
6.52B
41.4%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
206.3%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$12.6B
70.9% of FCF

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
3
Active Leaks
0/3
Improving
0
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating AbbVie Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
61
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
57
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing ABBV's balance between Growth (30.6%), Profitability (43.8%), and Safety (25.5%). Growth 31% Safety 26% Profitability 44%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

45th percentile vs peers
45
Key Signals
Rev Growth YoY 8.6% 63p Revenue CAGR 3Y 1.8% 31p EPS Growth YoY -12.0% 36p EPS CAGR 3Y -28.1% 37p TSR 32.3% 53p
Strengths
  • Gross Profit Margin in top 20% of peers (83.7%, 89th percentile)
  • Net Debt/Ebitda in top 20% of peers (4.13, 80th percentile)
  • Cash Flow To Debt Ratio in top 20% of peers (3.42, 82th percentile)
  • Consistently strong margins across 5 metrics
Risks

No significant risks identified for this axis.

Profitability

64th percentile vs peers
65
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

37th percentile vs peers
38
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for AbbVie Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$74.21
- - -
-66.2% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info